Critical Survey: TherapeuticsMD (TXMD) versus Advanced Accelerator Applications (AAAP)
TherapeuticsMD (NASDAQ: TXMD) and Advanced Accelerator Applications (NASDAQ:AAAP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitabiliy, dividends, valuation, institutional ownership and earnings.
Earnings and Valuation
This table compares TherapeuticsMD and Advanced Accelerator Applications’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|TherapeuticsMD||$18.41 million||59.37||-$90.40 million||N/A||N/A|
|Advanced Accelerator Applications||$133.77 million||16.35||-$14.42 million||($0.68)||-72.95|
Advanced Accelerator Applications has higher revenue and earnings than TherapeuticsMD.
This table compares TherapeuticsMD and Advanced Accelerator Applications’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Applications||-29.01%||-14.38%||-9.65%|
This is a summary of recent recommendations and price targets for TherapeuticsMD and Advanced Accelerator Applications, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Applications||0||1||4||0||2.80|
TherapeuticsMD presently has a consensus target price of $16.14, indicating a potential upside of 201.17%. Advanced Accelerator Applications has a consensus target price of $54.00, indicating a potential upside of 8.85%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, analysts clearly believe TherapeuticsMD is more favorable than Advanced Accelerator Applications.
Insider and Institutional Ownership
40.9% of Advanced Accelerator Applications shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Advanced Accelerator Applications beats TherapeuticsMD on 6 of the 10 factors compared between the two stocks.
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
About Advanced Accelerator Applications
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.